Forty-eight evaluable male patients with germ cell tumors (GCT) failing to be cured with first line therapy were treated with VP-16 (i00 mg/m2), ifosfamide (1.2 mg/m2), and cisplatin (~20 mg/m 2) all given daily for five consecutive days every three weeks.
All patients either achieved an unresectable partial remission as their best response to induction chemotherapy (Group A), relapsed from complete remission J 2 months after induction therapy (Group B), or had previously received eisplatin plus VP-16 as previous salvage therapy (Group C). In our experience, these three groups represented patients in whom conventional salvage therapy with cisplatin plus VP-16 alone rarely produced durable complete remissions. Nine (19%) had extragonadal GCT and 37 (77%) had advanced disease.
Twenty-three (48%) of the patients had > 2 prior treatment regimens.
Sixteen of 48 (33%) achieved a complete remission (CR) to VIP alone or following surgical excision of residual disease.
Six of 22 (27%), 3 of 7 (43%) and 7/19 (37%) of patients from groups A, B, and C respectively attained a CR. The median survival time of all patients was 7 months (range 0-28+) with 7 patients remaining continuously free of disease (4 patients > 1 year). Myelosuppression was significant with median WBC nadir of 900/mm 2 and platelet nadir of 24,000/mm 2. Fourteen (26%) had granulocytopenie fever and 15% developed renal insufficiency.
VIP combination chemotherapy demonstrates activity in this highly unfavorable population of patients with germ cell tumors. These results compare favorably to our previous experience in similar patients treated with eisplatin plus VP-16 alone suggesting an important role for ifosfamide in this disease. Although the prognosis of metastatic nonseminomatous testicular cancer has been dramatically improved during the past decades due to the development of combination chemotherapy, the search for new chemotherapeutic alternatives for salvage therapy has become one of the major challenges, Since 1977 we have investigated on the cytotoxic efficacy of ifosfamide alone (60mg/kg/dayiv, days I-5, q 21-28 days) or in combination with etoposide (40mg/kg/dav ifosfamide iv, days I-5, 120mg/m2/day etoposideiv, days~l,3, and 5, q 21-28 days} in 150 patients with metastatic nonseminomatous testicular cancer resistant against vinblastine, bleomycin, adriamycin, and cisplatinum.
Response rates -including minor responses-were 33% for ifosfamide (CR+PR 19%) and 46% for ifosfamide/etoposide (CR+PR 30%), respectively. The incidence of urinary tract complications, the dose limiting toxic side effect of ifosfamide, could be effectively reduced from 27% to 4% by coadministration of mesna (12mg/kgiv, O, 4, and 8h after ifosfamide).
Ifosfamide proved to be one of the most potent cytotoxic drugs in the primary treatment of metastatic seminomas, as well. Complete responses could be achieved in 16/17 patients (94%)by ifosfamide, ifosfamide/etoposide or ifosfamide/cisplatinum (40mg/kg/day ifosfamide iv, days I-5, 20mg/m2/ day cisplatinumiv, days I-5, q21-28 days). Presently, all complete responders have no evidence of disease at a medium follow up of 28 months.
In conclusion, ifosfamide/mesna-one of the most active cytotoxic agents in metastatic testicular cancer-may not only be included into effective combination chemotherapy regimens for salvage therapy but also in the first line treatment of this malignant disease. Within patient pharmacokinetics of (I) were determined following the administration of Ig and 2g p.o. and i.v. in seven patients with bronchial carcinoma. Serial serula and urine samples were collected during the first 48 hours after administration and concentrations of (I) were assayed by HPLC using a method developed in this laboratory.
The AUC (~g.L.h -I) for both the I and 2g doses were the same following p.o. and i.v. administration indicating 100% bioavailability (Table I ). The i.v. serum concentration/time curve exhibited a biphasic decay with a terminal half life of 5.92h (SD 1.15, SEN 0.47) for Ig and 5.29 (SD 0.73, SEM 0.27) for 2g. Drug clearance was similar for both methods of administration. We conclude that up to 2 g of (I) p.o. is an alternative route of a~ainistration and makes out patient use a possibility. 
